Executive Summary Commercial success is rarely determined by the quality of the science alone. Every year biotechnology companies invest hundreds of millions of dollars advancing promising therapies through clinical development. Yet many products fail commercially despite strong clinical data. The reasons are often attributed to reimbursement, competition, physician adoption, or market conditions. Those factors matter—but they are usually symptoms rather than the underlying cause. The most successful commercial organizations are…
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
